JP2014508720A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508720A5
JP2014508720A5 JP2013543275A JP2013543275A JP2014508720A5 JP 2014508720 A5 JP2014508720 A5 JP 2014508720A5 JP 2013543275 A JP2013543275 A JP 2013543275A JP 2013543275 A JP2013543275 A JP 2013543275A JP 2014508720 A5 JP2014508720 A5 JP 2014508720A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
group
formula
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013543275A
Other languages
English (en)
Japanese (ja)
Other versions
JP6076913B2 (ja
JP2014508720A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/063533 external-priority patent/WO2012078633A2/en
Publication of JP2014508720A publication Critical patent/JP2014508720A/ja
Publication of JP2014508720A5 publication Critical patent/JP2014508720A5/ja
Application granted granted Critical
Publication of JP6076913B2 publication Critical patent/JP6076913B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013543275A 2010-12-07 2011-12-06 癌からの転移を阻害する方法 Expired - Fee Related JP6076913B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42064010P 2010-12-07 2010-12-07
US61/420,640 2010-12-07
PCT/US2011/063533 WO2012078633A2 (en) 2010-12-07 2011-12-06 Methods of inhibiting metastasis from cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017002396A Division JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Publications (3)

Publication Number Publication Date
JP2014508720A JP2014508720A (ja) 2014-04-10
JP2014508720A5 true JP2014508720A5 (enExample) 2015-01-29
JP6076913B2 JP6076913B2 (ja) 2017-02-08

Family

ID=46162450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013543275A Expired - Fee Related JP6076913B2 (ja) 2010-12-07 2011-12-06 癌からの転移を阻害する方法
JP2017002396A Pending JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017002396A Pending JP2017122085A (ja) 2010-12-07 2017-01-11 癌からの転移を阻害する方法

Country Status (4)

Country Link
US (4) US8435993B2 (enExample)
EP (1) EP2648754A4 (enExample)
JP (2) JP6076913B2 (enExample)
WO (1) WO2012078633A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8883989B2 (en) * 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
CN104245735B (zh) * 2012-02-27 2018-02-23 勃林格殷格翰国际有限公司 Cx3cr1结合多肽
JP2016534114A (ja) * 2013-08-21 2016-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cx3cr1標的化イメージング剤並びに疾病の診断及び処置におけるその使用
WO2016024096A1 (en) * 2014-08-11 2016-02-18 Redx Pharma Plc Antibacterial compounds
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
WO2019014122A1 (en) * 2017-07-08 2019-01-17 The Brigham And Women's Hospital, Inc. METHODS FOR ENHANCING ANTIANGIOGENIC THERAPY AND IMMUNOTHERAPY
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP4003972A4 (en) * 2019-07-23 2023-07-12 Board of Regents, The University of Texas System BICYCLIC RECEPTOR AGONISTS
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス4 ファーマシューティカルズ, インコーポレイテッド 好中球減少症を処置する方法
CN116075512A (zh) 2020-06-11 2023-05-05 Chdi基金会股份有限公司 用于对亨廷顿蛋白成像的杂环化合物和显像剂
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939159A (en) * 1974-05-29 1976-02-17 American Hoechst Corporation Spiro(pyrrolo (1,2-A)quinoxalines)
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
AU2000273378A1 (en) 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US20020010125A1 (en) 2000-03-16 2002-01-24 Carson Dennis A. Assay for agents that induce chemokinesis
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003052082A2 (en) 2001-12-18 2003-06-26 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
WO2005033115A1 (en) * 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
US20060115834A1 (en) * 2004-10-19 2006-06-01 University Of Iowa Research Foundation Methods of identifying metastatic potential in cancer
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
RU2437889C2 (ru) 2006-09-29 2011-12-27 Астразенека Аб НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
KR20140139125A (ko) * 2007-08-31 2014-12-04 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
EP2262778B8 (en) * 2008-03-07 2020-01-01 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
AR071036A1 (es) 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
JP5351254B2 (ja) * 2008-05-23 2013-11-27 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
MX2011002636A (es) * 2008-09-11 2011-04-05 Chemocentryx Inc 4-amino-3-(imidazoil)-pirazolo[3,4-d]pirimidinas.
JP2011127042A (ja) 2009-12-18 2011-06-30 Fujifilm Corp アゾ顔料、アゾ顔料の製造方法、アゾ顔料を含む分散物、及び着色組成物
US8785490B2 (en) * 2010-04-09 2014-07-22 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer

Similar Documents

Publication Publication Date Title
JP2023514872A5 (enExample)
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2020505356A5 (enExample)
US20130150385A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
JP2010502751A5 (enExample)
JP2011509309A5 (enExample)
RU2015139590A (ru) ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ
JP2013518129A5 (enExample)
JP2014528464A5 (enExample)
JP2009536620A5 (enExample)
JP2015524472A5 (enExample)
JP2014500265A5 (enExample)
JP2005517006A5 (enExample)
JP2016510785A5 (enExample)
JP2013523814A5 (enExample)
JP2026020169A (ja) Rho関連コイルドコイル含有プロテインキナーゼの阻害剤
JP7849141B2 (ja) がんの治療のためのnox阻害剤の使用
JP2019525948A5 (enExample)
JP2022535734A5 (enExample)
JP2010536821A5 (enExample)
JP2022500428A5 (enExample)
JP2016540811A5 (enExample)
JP2021527693A5 (enExample)
JP2024507414A5 (enExample)